Literature DB >> 17105851

A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents.

C Ritchlin, F Tausk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17105851      PMCID： PMC1798464          DOI： 10.1136/ard.2006.059261

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  37 in total

1.  Glucocorticoid-induced TNF receptor functions as a costimulatory receptor that promotes survival in early phases of T cell activation.

Authors:  Edward M Esparza; Robert H Arch
Journal:  J Immunol       Date:  2005-06-15       Impact factor: 5.422

2.  Tumour necrosis factor inhibition causing psoriasis? A more plausible explanation exists.

Authors:  J D Carter
Journal:  Ann Rheum Dis       Date:  2006-12       Impact factor: 19.103

3.  Staphylococcal toxins in patients with psoriasis, atopic dermatitis, and erythroderma, and in healthy control subjects.

Authors:  Nordwig Sebastian Tomi; Birger Kränke; Elisabeth Aberer
Journal:  J Am Acad Dermatol       Date:  2005-07       Impact factor: 11.527

4.  Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia.

Authors:  E Ladoyanni; R Nambi
Journal:  J Drugs Dermatol       Date:  2005 Mar-Apr       Impact factor: 2.114

5.  Infliximab in the treatment of moderate to severe atopic dermatitis.

Authors:  Arnd Jacobi; Christian Antoni; Bernhard Manger; Gerold Schuler; Michael Hertl
Journal:  J Am Acad Dermatol       Date:  2005-03       Impact factor: 11.527

6.  Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.

Authors:  P P Sfikakis; A Iliopoulos; A Elezoglou; C Kittas; A Stratigos
Journal:  Arthritis Rheum       Date:  2005-08

7.  Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins.

Authors:  Rainer Zenz; Robert Eferl; Lukas Kenner; Lore Florin; Lars Hummerich; Denis Mehic; Harald Scheuch; Peter Angel; Erwin Tschachler; Erwin F Wagner
Journal:  Nature       Date:  2005-09-15       Impact factor: 49.962

8.  Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B.

Authors:  Ioannis Ketikoglou; Stelios Karatapanis; Ioannis Elefsiniotis; Georgia Kafiri; Antonios Moulakakis
Journal:  Eur J Dermatol       Date:  2005 Mar-Apr       Impact factor: 3.328

9.  Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.

Authors:  Marcel Flendrie; Wynand H P M Vissers; Marjonne C W Creemers; Elke M G J de Jong; Peter C M van de Kerkhof; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2005-04-04       Impact factor: 5.156

10.  Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

Authors:  Frank O Nestle; Curdin Conrad; Adrian Tun-Kyi; Bernhard Homey; Michael Gombert; Onur Boyman; Günter Burg; Yong-Jun Liu; Michel Gilliet
Journal:  J Exp Med       Date:  2005-07-04       Impact factor: 14.307
View more
  5 in total

1.  Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.

Authors:  K Vandevyvere; F P Luyten; P Verschueren; R Lories; S Segaert; R Westhovens
Journal:  Clin Rheumatol       Date:  2007-09-18       Impact factor: 2.980

2.  Chronic social stress Ameliorates psoriasiform dermatitis through upregulation of the Hypothalamic-Pituitary-Adrenal axis.

Authors:  Oscar Vegas; Brian Poligone; Paul Blackcloud; Elaine S Gilmore; JoAnne VanBuskirk; Christopher T Ritchlin; Alice P Pentland; Scott A Walter; Yasmine Nousari; Francisco Tausk
Journal:  Brain Behav Immun       Date:  2017-11-07       Impact factor: 7.217

3.  Adalimumab-induced psoriasis in a patient with Crohn's disease.

Authors:  Ugur Korkmaz; Ali Erkan Duman; Gokhan Dindar; Hasan Yilmaz; Ibrahim Hakki Dursun; Altay Celebi; Omer Senturk; Sadettin Hulagu
Journal:  Indian J Gastroenterol       Date:  2013-03

4.  Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

Authors:  M J Harrison; W G Dixon; K D Watson; Y King; R Groves; K L Hyrich; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2008-04-02       Impact factor: 19.103

5.  The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis.

Authors:  Natalia P Machado; Edgard Torres dos Reis Neto; Maria Roberta M P Soares; Daniele S Freitas; Adriana Porro; Rozana M Ciconelli; Marcelo M Pinheiro
Journal:  Clinics (Sao Paulo)       Date:  2013-09       Impact factor: 2.365
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.